| Autor: |
G, Fattovich, G, Giustina, J, Sanchez-Tapias, C, Quero, A, Mas, P G, Olivotto, A, Solinas, P, Almasio, S, Hadziyannis, F, Degos, M C, de Moura, K, Krogsgaard, M, Pantalena, G, Realdi, R, Corrocher, S W, Schalm |
| Rok vydání: |
1998 |
| Předmět: |
|
| Zdroj: |
The American journal of gastroenterology. 93(6) |
| ISSN: |
0002-9270 |
| Popis: |
The aim of this study was to evaluate the incidence, prognostic factors and clinical significance of delayed clearance of serum HBsAg in compensated cirrhosis B.This was a retrospective cohort study of 309 consecutive white patients with biopsy-proved compensated cirrhosis type B.During a mean follow-up of 68 months, HBsAg loss occurred in 32 patients, including 16 (8%) of 196 untreated patients (mean annual incidence 0.8%), 8 (10%) of 82 interferon (IFN) alpha-treated patients and eight patients who had been treated with other antivirals or steroids. The 5-yr probability of HBsAg loss was 4% and 16% for untreated and IFN-treated patients, respectively (p = 0.0001). Cox's regression analysis identified hepatitis B e antigen-positivity at entry as the sole independent prognostic factor for HBsAg loss. Of the 32 patients who lost HBsAg, one (3%) subsequently developed hepatocellular carcinoma (HCC) and died, whereas, among the patients who remained HBsAg-positive, 11% developed HCC and 20% had died. The probability of HCC appearance was lower (p = 0.0137) and survival was longer (p = 0.0006) in patients who cleared HBsAg compared with patients with HBsAg persistence.The incidence of HBsAg loss is about 0.8% in cirrhosis type B. Prognostic factors for clearance of HBsAg are initial HBeAg positivity and therapy with alpha interferon. Patients with cirrhosis type B, who lose HBsAg, have a low risk for liver cancer or liver-related death. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
